WO2005123762A3 - Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16 - Google Patents

Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16 Download PDF

Info

Publication number
WO2005123762A3
WO2005123762A3 PCT/IB2005/001725 IB2005001725W WO2005123762A3 WO 2005123762 A3 WO2005123762 A3 WO 2005123762A3 IB 2005001725 W IB2005001725 W IB 2005001725W WO 2005123762 A3 WO2005123762 A3 WO 2005123762A3
Authority
WO
WIPO (PCT)
Prior art keywords
organism
hpv16
prokaryotic micro
human papillomavirus
codon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001725
Other languages
French (fr)
Other versions
WO2005123762B1 (en
WO2005123762A2 (en
Inventor
Denise Nardelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indian Immunologicals Ltd
Original Assignee
Indian Immunologicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Immunologicals Ltd filed Critical Indian Immunologicals Ltd
Priority to JP2007516066A priority Critical patent/JP4769247B2/en
Priority to CN2005800278872A priority patent/CN101115766B/en
Publication of WO2005123762A2 publication Critical patent/WO2005123762A2/en
Publication of WO2005123762A3 publication Critical patent/WO2005123762A3/en
Publication of WO2005123762B1 publication Critical patent/WO2005123762B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a novel nucleic acid sequence (HPV16 L1S) encoding antigenic HPV16 L1 protein as provided in SEQ ID NO: 1, wherein the said sequence has atleast one modified codon for optimum stability of recombinant plasmid vector when transformed in the prokaryotic micro-organism for improved immunogenicity of the resulting prokaryotic micro-organism. The invention further relates to constructing recombinant vectors pFS14nsdHPV16L1 and pFS14nsdHPV16 kan L1S harboring SEQ ID NO: 1, wherein the former carries Ampicillin and the latter, Kanamycin as a selection marker. The invention also relates to an attenuated strain of a prokaryotic micro-organism transformed with nucleic acid encoding HPV16 (Human Papillomavirus) major capsid protein and expressing the corresponding protein. In addition the invention discloses a process of producing a vaccine based on prokaryotic micro-organism for the treatment of papillomavirus infection and associated risk of cancer.
PCT/IB2005/001725 2004-06-18 2005-06-20 Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16 Ceased WO2005123762A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007516066A JP4769247B2 (en) 2004-06-18 2005-06-20 Codon optimized HPV16L1 for Salmonella vaccine strain against human papillomavirus type 16
CN2005800278872A CN101115766B (en) 2004-06-18 2005-06-20 Codon-optimized HPV16LI for salmonella vaccine strains against human papillomavirus type 16

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2004000373 2004-06-18
CHPCT/CH2004/000373 2004-06-18

Publications (3)

Publication Number Publication Date
WO2005123762A2 WO2005123762A2 (en) 2005-12-29
WO2005123762A3 true WO2005123762A3 (en) 2006-04-27
WO2005123762B1 WO2005123762B1 (en) 2006-06-08

Family

ID=35510322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001725 Ceased WO2005123762A2 (en) 2004-06-18 2005-06-20 Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16

Country Status (3)

Country Link
JP (1) JP4769247B2 (en)
CN (1) CN101115766B (en)
WO (1) WO2005123762A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
CN100532548C (en) * 2007-02-14 2009-08-26 马润林 Method of increasing yield of human papilloma virus L1 albumen pronucleus expression
CN102178944A (en) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 Expression and application of human papilloma viruses type 16 and 18 L1 proteins in inset cells
MX364922B (en) * 2013-04-25 2019-05-14 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1.
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
CN104513826B (en) * 2013-09-29 2020-10-20 上海泽润生物科技有限公司 Human papilloma virus gene, vector, strain and expression method
CN107002085A (en) * 2014-09-11 2017-08-01 卡迪拉保健有限公司 Excellent human papillomavirus antigen with superior immune characteristic and the vaccine containing it
RU2628693C1 (en) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) Recombinant l1hpv16 gene, recombinant pqe-l1/16 plasmid, l1hpv16 protein and their application
CN113528544B (en) * 2021-06-02 2022-07-08 郑州大学 Gene for coding soluble HPV23L1 protein and construction and application of recombinant plasmid thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025328A1 (en) * 1996-10-09 2002-02-28 Denise Nardelli Haefliger Attenuated microorganism strains expressing hpv proteins
WO2004084831A2 (en) * 2003-03-24 2004-10-07 Merck & Co. Inc. Optimized expression of hpv 31 l1 in yeast

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025328A1 (en) * 1996-10-09 2002-02-28 Denise Nardelli Haefliger Attenuated microorganism strains expressing hpv proteins
WO2004084831A2 (en) * 2003-03-24 2004-10-07 Merck & Co. Inc. Optimized expression of hpv 31 l1 in yeast

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAUD DAVID ET AL: "Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar typhimurium.", INFECTION AND IMMUNITY, vol. 72, no. 2, February 2004 (2004-02-01), pages 750 - 756, XP002364716, ISSN: 0019-9567 *
BAUD DAVID ET AL: "Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1", JOURNAL OF VIROLOGY, vol. 78, no. 23, December 2004 (2004-12-01), pages 12901 - 12909, XP002364715, ISSN: 0022-538X *
LEDER C ET AL: "Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 19, October 2001 (2001-10-01), pages 9201 - 9209, XP002202893, ISSN: 0022-538X *
SEEGERS J F M L: "Lactobacilli as live vaccine delivery vectors: progress and prospects", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 20, no. 12, 1 December 2002 (2002-12-01), pages 508 - 515, XP004393459, ISSN: 0167-7799 *
WYSZYNSKA A ET AL: "Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 11-12, 29 March 2004 (2004-03-29), pages 1379 - 1389, XP004500381, ISSN: 0264-410X *

Also Published As

Publication number Publication date
CN101115766A (en) 2008-01-30
JP2008504020A (en) 2008-02-14
WO2005123762B1 (en) 2006-06-08
CN101115766B (en) 2013-05-08
WO2005123762A2 (en) 2005-12-29
JP4769247B2 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
NZ598703A (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
KR101196178B1 (en) Fusion protein of hiv regulatory/accessory proteins
JP2005523716A5 (en)
CA2573702A1 (en) Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
WO2005123762A3 (en) Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16
WO2003072719A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
CA2222129A1 (en) A method for producing influenza hemagglutinin multivalent vaccines
CN102112152A (en) Vaccine composition suitable for HPV and hepatitis B infection and its preparation method
WO2007095320A4 (en) Hpv antigens, vaccine compositions, and related methods
MXPA02006888A (en) Recombinant flaviviruses and methods of use thereof.
MX2014006520A (en) Hpv chimaeric particle.
WO2008127179A8 (en) Fusion protein vaccine
CN101934072B (en) Method for preparing App bacterial ghost and method for preparing subunit vaccine by loading pasteurella antigen in App bacterial ghost
RU2011133057A (en) STABLE VECTOR OF CONSTITUTIONALLY HIGH EXPRESSION FOR OBTAINING HPV VACCINES AND RECOMBINANT LACTIC-ACID BACTERIA TRANSFORMED WITH THIS VECTOR
CN108359677A (en) The method for improving porcine circovirus 2 type and 3 type Cap protein expressing in series efficiency
WO2002081709A3 (en) Modified hpv e6 and e7 genes and proteins useful for vaccination
CN110016458B (en) Engineering strain for fermenting and synthesizing alpha-bisabolol and construction method thereof
WO2003097673B1 (en) Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles.
CN104119441A (en) Bovine A-type foot-and-mouth disease broad-spectrum multi-epitope vaccine, and preparation method and application thereof
AU2019226487B2 (en) Expression of Pneumococcal Surface Protein A (PSPA)
CN104119443B (en) Broad-spectrum multi-epitope recombinant vaccine for bovine foot-and-mouth disease virus type A strain epidemic abroad, and preparation method and application thereof
CN116785422B (en) Measles attenuated vaccine containing novel coronavirus combined antigen and rescue method thereof
PT1962889E (en) Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof
JP2008504020A5 (en)
CA2560539A1 (en) Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20060411

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 12006502512

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2007516066

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 131/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580027887.2

Country of ref document: CN

122 Ep: pct application non-entry in european phase
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)